Immunology
HIV drug switch linked to fewer signs of immune-cell aging
Over 48 weeks, 37 adults switching to injectable HIV drugs had larger declines in immune-cell activation and aging markers than nine continuing oral drugs.Over 48 weeks, 37 adults switching to injectable HIV drugs had larger declines in immune-cell activation and aging markers than nine continuing oral drugs.
Cohort studyBlood and immune system
Who was studiedAdults with suppressed HIV, 72 weeks, against people continuing oral ART
What changedImmune-cell aging markers fell more in adults switching to injectable HIV drugs than in those continuing oral drugs
The catchThe comparison group contained only nine people